VLST lands $55M second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
VLST
|
$55M
|
Texas Pacific Group Ventures |
VLST is studying the way in which viruses attack immune systems in order to devise new therapies for multiple sclerosis, psoriasis and lupus. |
|
Tengion
|
$50M
|
Quaker BioVentures, Bain Capital |
Tengion is developing a method for making replacement organs from the cells of patients. |
|
Rib-X
|
$50M
|
Warburg Pincus |
Rib-X is researching next-gen antibiotics. |
|
Adnexus Therapeutics
|
$27M
|
Venrock Associates |
Adnexus is researching a class of protein therapeutics. |
|
GlycoMimetics
|
$15.4M
|
New Enterprise Associates |
GlycoMimetics is developing novel drug therapies based on specific roles played by certain carbohydrates. |